Value-based care (VBC) in ophthalmology ties payments to the quality of care delivered rather than the volume of services. The goal is straightforward: better outcomes for patients at a more manageable cost.
This article is intended for ophthalmologists, healthcare administrators, and policy makers interested in improving patient outcomes and cost-effectiveness in eye care.
However, there are rising concerns about healthcare costs in the United States, as healthcare spending now accounts for a significant and growing percentage of the nation’s gross domestic product. These concerns highlight the need for more efficient and value-driven healthcare delivery.
This article is aimed at ophthalmologists, healthcare administrators, and policy makers interested in practical approaches to improving eye care while keeping costs in check.
It is important to note that the majority of ophthalmologic interventions studied to date are cost-effective, largely because patients place a high value on their vision.
Key Takeaways
- Value-based care links payment to patient outcomes, not service volume.
- Cost-effectiveness analysis is essential. Not all treatments deliver equal value per dollar.
- Successful implementation depends on reliable data, integrated care delivery, and clear outcome measures.
What Value-Based Care Means in Ophthalmology
Value-based healthcare (VBHC) shifts the focus from how much care is delivered to how well it works.
Value-based care in ophthalmology aims to improve patient outcomes while controlling costs. Success is measured by patient-reported outcomes, such as improvements in visual acuity and patient satisfaction. The patient-perceived value of interventions can be compared using quality-adjusted life years (QALY) as a common outcome measure.
Foundational concepts underpinning value-based healthcare include organizing care around patient value and outcomes, drawing from frameworks adapted from other industries to improve efficiency in ophthalmology. In ophthalmology, this means evaluating everything, from routine exams to complex surgeries, based on the value it provides to patients.
Outcomes are measured through patient-reported results, such as improvements in visual acuity and quality of life. Quality-adjusted life years (QALYs) are the standard unit used to compare the value of different interventions across conditions. A score of 1.0 represents perfect health. QALY methodology allows for comparison of cost-effectiveness of medical, pharmacologic, and surgical interventions within and across specialties, serving as a common outcome measure for patient-perceived value.
Integrated Practice Units (IPUs) organize care around specific patient conditions rather than medical specialties. Using a systematic approach to organizing care, such as through IPUs, enhances coordination among providers, reduces duplication, and leads to more efficient treatment pathways.
Principles of Value-Based Medicine
Value-based medicine is transforming healthcare by emphasizing quality care and efficient use of resources. At its core, value-based medicine prioritizes patient-centered care, ensuring that every treatment decision is guided by the best available evidence and a thorough cost-benefit analysis. In ophthalmology, this means evaluating the effectiveness of interventions like cataract surgery and anti-VEGF therapy for conditions like age-related macular degeneration not just by clinical outcomes, but by the value they deliver to patients’ lives.
Providers use evidence-based treatment protocols to determine which therapies offer the greatest improvement in vision and quality of life for the lowest cost. For example, when considering options for age-related macular degeneration, clinicians weigh the clinical outcomes and cost-effectiveness of anti-VEGF agents to select the most appropriate treatment. By systematically applying value-based medicine, ophthalmology practices can deliver higher quality care, optimize resource allocation, and achieve better outcomes for patients while managing overall healthcare costs.
The Policy Background
The shift toward VBC in ophthalmology gained momentum with federal legislation, specifically the Medicare Access and CHIP Reauthorization Act (MACRA), signed in 2015. MACRA established the Quality Payment Program (QPP), a new program designed to drive the transition to value-based care by establishing structured processes and policies. The QPP introduced the Merit-Based Incentive Payment System (MIPS), fundamentally changing how Medicare reimburses ophthalmology practices. For 2023, MIPS performance thresholds allow for payment adjustments of up to 9% on all Medicare-submitted claims, and a final MIPS score of 75 points or more is required to avoid a negative payment adjustment. MIPS Value Pathways (MVPs) have also been introduced to reduce reporting burdens and are specialty-specific, making it easier for ophthalmologists to align with value-based care requirements. The shift from volume-based to value-based care requires establishing fair compensation policies for physicians to ensure equitable reimbursement. MIPS reporting requirements are designed to promote quality care and value in healthcare, benefiting both patients and ophthalmologists.
Accountable Care Organizations (ACOs) have been central to this transition. Nearly 60% of physicians have participated in value-based arrangements since 2014. Ophthalmologists in ACOs should note that CMS will prioritize the ACO’s quality performance reporting over individual practice reporting, so knowing what ACO you’re part of matters.
Role of Payers in Value-Based Care
Health insurance companies and Medicaid services are pivotal in advancing value-based care in ophthalmology. By designing value-based payment models that reward providers for delivering high-quality, cost-effective services, payers help shift the focus from volume to value. These models, which include alternatives to traditional fee-for-service, encourage providers to follow clinical guidelines and treatment protocols that emphasize both patient outcomes and cost effectiveness.
Payers also collaborate with healthcare providers to develop and refine clinical guidelines that support evidence-based, patient-centered care. This partnership ensures that patients receive treatments that are proven to deliver value, while also helping to control costs and improve the quality of services. By aligning incentives and supporting the adoption of value-based care, payers play a crucial role in creating a healthcare system that delivers better outcomes for patients and more sustainable costs for all stakeholders.
Cost-Effectiveness in Practice
Cost-effectiveness is a real issue in ophthalmology, particularly for conditions like age-related macular degeneration (wet AMD) and diabetic macular edema (DME), where anti-VEGF therapies are the standard of care but vary significantly in cost.
For example:
- Ranibizumab costs over $58,000 per patient over 25 years, with an incremental cost-effectiveness ratio (ICER) of over $89,000 per QALY, above the threshold many payers consider cost-effective.
- Bevacizumab costs approximately $27,200 over the same period, with an ICER of around $11,138 per QALY for clinically significant DME, making it the most cost-effective option among evaluated therapies.
The number of injections required significantly affects overall cost. Potential side effects, such as cerebrovascular events, also factor into the full cost model.
Cost-effectiveness ratios are often illustrated using visual aids to compare interventions and outcomes. Medicare reimbursement rates are commonly used to estimate costs in cost-utility analyses, providing a standardized approach for economic evaluations. Societies must determine how much they are willing to pay for effective interventions, referencing cost-utility standards to guide funding priorities. In a review of the literature, a total of 19 papers were found, including 25 interventions evaluated for cost-utility in ophthalmology. The median cost-utility of ophthalmologic interventions was $5,219/QALY, with a range from $746/QALY to $6.5 million/QALY. Quality-adjusted life years (QALY) is used as a common outcome measure to compare the patient-perceived value of healthcare interventions.
Cataract surgery on the first eye, for instance, produces a 20.8% improvement in quality of life and delivers substantial value to both the patient and society.
Measuring Outcomes
Consistent measurement is what makes VBC work. Without it, you can’t manage what you can’t measure.
The IRIS Registry, maintained by the American Academy of Ophthalmology, is the largest clinical registry in ophthalmology. It supports outcome tracking by:
- Giving practices direct access to performance reports
- Aggregating data for population health analysis
- Verifying adherence to clinical guidelines
The IRIS Registry also enables benchmarking performance with colleagues and learning from other practices, helping providers identify opportunities for improvement and adopt best practices.
Patient-reported outcome measures (PROMs) and patient experience measures (PREMs) complement clinical data by capturing the patient’s perspective, how their condition affects their daily life, independence, and well-being. Completing outcome assessments is essential to fully evaluate treatment effectiveness and ensure that interventions deliver meaningful improvements for patients. These are critical inputs that clinical metrics like visual acuity alone don’t capture.
Electronic health records (EHRs) support standardization across practices, reducing variability in care and enabling meaningful comparisons of outcomes and costs. The implementation of electronic medical records is essential for collecting important outcomes metrics in ophthalmology.
Clinical Data Registries
Clinical data registries are foundational to advancing quality and value in ophthalmic care. These registries, such as the IRIS Registry, enable providers to systematically collect and analyze data on clinical outcomes, treatment protocols, and patient populations. By participating in clinical data registries, ophthalmology practices can benchmark their performance, identify opportunities for improvement, and contribute to the development of evidence-based standards.
Registries support continuous quality improvement by highlighting which treatments and protocols yield the best outcomes. This data-driven approach empowers providers to refine their practices, reduce unnecessary variation, and optimize resource use. Ultimately, clinical data registries help ensure that ophthalmic care is both high-quality and cost-effective, benefiting patients and the broader healthcare system.
Lean Principles in Ophthalmology
Applying lean principles in ophthalmology offers a proven strategy for enhancing efficiency and patient care. Lean methodologies focus on streamlining workflows, minimizing waste, and making the best use of available resources. In practice, this can mean redesigning clinic processes to reduce waiting times, standardizing surgical procedures, and improving coordination among care teams.
For example, implementing lean principles in cataract surgery can lead to shorter surgical times, more predictable scheduling, and improved patient outcomes. By continuously evaluating and refining clinical processes, providers can deliver higher quality care, increase patient satisfaction, and reduce costs. Lean thinking empowers ophthalmology practices to create more value for patients and the healthcare system as a whole.
Patient-Centered Care
Patient-centered care is at the heart of value-based medicine, especially in ophthalmology. This approach means putting patients’ needs, preferences, and values at the forefront of every clinical decision. Providers engage patients through education, shared decision-making, and personalized treatment plans, ensuring that care is tailored to each individual’s unique circumstances.
By fostering open communication and supporting patients in understanding their treatment options, ophthalmology practices can improve satisfaction and health outcomes. Patient-centered care also addresses the social and emotional aspects of eye health, recognizing that quality care extends beyond clinical measures. Ultimately, this approach leads to better outcomes, more efficient use of healthcare resources, and greater value for both patients and providers.
Technology and Point-of-Care Decision Support
Technology is a practical enabler of VBC, not just a theoretical one. Tools that make a measurable difference include:
- EHR-integrated decision support platforms that surface evidence-based treatment options at the point of care
- Teleophthalmology, which improves access and patient engagement
- Patient portals and mobile apps, shown to increase treatment adherence and satisfaction
- AI and advanced analytics, increasingly integrated into registries like IRIS to improve predictive modeling and identify high-risk patients for proactive intervention
One concrete example: Outcomes Matter Innovations’ (OMI) PULSE platform integrates into existing clinical workflows, enabling ophthalmologists to make well-informed treatment decisions while improving both affordability and patient outcomes. It identifies patients eligible for optimized treatments, collects clinical outcomes data, and eliminates prior authorization burdens for providers and payers.
Real-World Results
Case studies show VBC principles work when applied systematically. Coordinated efforts among clinical teams, adherence to guidelines, and cost-control strategies are essential for successful implementation and measurement of value-based care initiatives in ophthalmology:
- In the Netherlands, a five-year glaucoma care redesign at Rotterdam Eye Hospital applied a quality cost model and care delivery value chain, reducing cost per case while improving patient satisfaction.
- In Canada, TDABC applied to cataract surgery at the Kensington Eye Institute generated detailed process maps and cost data that enabled data-driven resource optimization while preserving clinical outcomes.
- In Singapore, a value-driven outcomes (VDO) program for cataract surgery implemented at National University Hospital reduced per-case costs by over 300 USD while maintaining high outcome quality, illustrating the impact of systematic cost-and-outcome measurement in an integrated eye care setting.
OMI has partnered with over 250 ophthalmologists on the East Coast, saving partners more than $5M annually, with over 94% of patients maintaining visual acuity from visit to visit across more than 30,000 outcomes collected.
The Challenges
Implementing VBC in ophthalmology is not without friction and raises concerns about data collection, integration, and defining value:
- Collecting PROMs is difficult. Participant compliance and missing data are ongoing problems.
- Many practices lack the data infrastructure needed to track outcomes and costs comprehensively.
- The IRIS Registry, while valuable, has gaps, including missing systemic health data and variability in documentation practices across EHR sources.
- Integrating care across different facilities remains a logistical challenge.
- There is no universal agreement on what “value” means across different stakeholders. A consistent strategic framework with defined outcome measures is essential.
Value-based medicine incorporates patient-perceived quality of life parameters that are often ignored in traditional evidence-based medicine, which presents both an opportunity and a challenge for ophthalmology value-based care.
Payment Model Transition
Shifting from fee-for-service to value-based payment models requires careful planning. Bundled payments, covering an entire care episode rather than individual services, are one mechanism that aligns incentives with outcomes. Medicare’s MIPS framework is the current primary vehicle for most ophthalmology practices.
Historically, providers have been hesitant to enter VBC arrangements because of financial exposure from treatment adjustments and delayed savings payouts. OMI’s value-based care model addresses this by offering upfront financial protection, timely shared savings payments, and reduced administrative burden, eliminating common barriers like prior authorization requirements.
What’s Ahead
No healthcare system has fully adopted all the principles of value-based care, but the direction is clear. Ophthalmology is ahead of many specialties in terms of data infrastructure and outcomes measurement, but there is still significant ground to cover, particularly in connecting ophthalmology data to broader systemic health records, and in extending VBC models beyond retina into areas like glaucoma and cataract care.
There is growing interest among policymakers and stakeholders in advancing value-based medicine in ophthalmology, with a focus on integrating cost-utility and value-based approaches into healthcare systems and reimbursement policies. Value-based care also emphasizes a proactive and preventative approach to eye health, focusing on early detection and management of diseases. Additionally, future value-based care models should consider the importance of the second eye, as bilateral eye conditions and vision in the fellow eye can significantly impact patient quality of life and utility values.
Policy makers and providers need to simplify the alternative payment landscape to encourage broader participation. Mandatory participation frameworks are expected to be in place by 2028.
The fundamental principle holds: when you can measure outcomes, you can manage them, and that’s what value-based care is built on.
Frequently Asked Questions
What is value-based care in ophthalmology?
It ties payment to patient outcomes and care quality, not the number of services delivered. Providers are rewarded for results, not volume.
How does VBC improve cost-effectiveness?
By steering providers toward treatments that deliver the best outcomes per dollar. For example, bevacizumab delivers comparable clinical results to ranibizumab at a fraction of the cost for many retinal conditions.
What are the main challenges in implementing VBC in ophthalmology?
Data collection, care integration, and getting all stakeholders to agree on what outcomes matter most. Accurate measurement of both outcomes and costs is non-negotiable for the model to work.
How does technology support VBC in ophthalmology?
Through clinical decision support at the point of care, real-time cost and outcome tracking, and patient engagement tools. These reduce administrative burden and improve the quality and consistency of decisions.